Eton Pharmaceutcials, Inc. (ETON) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 8, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 13, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the ETON SEC filings page.
Eton Pharmaceutcials, Inc. (ETON) reported $105.6M in revenue over the twelve months to Jun 30, 2026, up 81.5% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 8 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Revenue nearly doubled in FY2025, but lower gross margins and heavy interest kept the company loss-making despite positive cash generation.
The cash-to-earnings gap is unusually wide: FY2025 reported a net loss of$4.6M while operating cash flow reached$10.5M . EBITDA was positive, yet depreciation and interest expense pushed earnings below zero, meaning current cash generation looks materially better than the bottom-line result.
Revenue roughly doubled from FY2024 to FY2025 while gross margin fell from
Debt-to-equity declined from 1.2x to 0.8x as equity expanded, but the current ratio fell from 2.1x to 1.6x. The balance sheet therefore became less leveraged on an equity basis while retaining a narrower short-term liquidity cushion, and retained losses remained substantial.
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Eton Pharmaceutcials, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Eton Pharmaceutcials, Inc. held $25.9M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations generated $10.5M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and Eton Pharmaceutcials, Inc. scores 86/100 among other emerging companies.
Eton Pharmaceutcials, Inc. had 27M shares outstanding at the end of fiscal year 2025, against 27M in fiscal year 2024. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and Eton Pharmaceutcials, Inc. scores 62/100 among other emerging companies.
Eton Pharmaceutcials, Inc. spent $7.8M on research and development in fiscal year 2025, which was 9.6% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and Eton Pharmaceutcials, Inc. scores 35/100 among other emerging companies.
Eton Pharmaceutcials, Inc. reported revenue of $80.0M in fiscal year 2025, against $39.0M in fiscal year 2024. Revenue Progress ranks emerging companies on the three-year path of that line, and Eton Pharmaceutcials, Inc. scores 81/100 among other emerging companies.
Not available for Eton Pharmaceutcials, Inc., and counted as zero in the overall score.
Eton Pharmaceutcials, Inc.'s cash, cash equivalents and investments came to $25.9M at the end of fiscal year 2025, against $66.0M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and Eton Pharmaceutcials, Inc. scores 39/100 among other emerging companies.
Eton Pharmaceutcials, Inc. scores 13.68, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($1.6B) relative to total liabilities ($66.0M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Eton Pharmaceutcials, Inc. passes 5 of 9 financial strength tests. 3 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.
Eton Pharmaceutcials, Inc. reported a net loss of $4.6M while generating $10.5M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal.
Eton Pharmaceutcials, Inc. reported an operating loss of $844K against $4.8M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Eton Pharmaceutcials, Inc. generated $37.6M in revenue in Q2 2026. This represents an increase of 98.6% from the same quarter a year earlier. Against the prior quarter it is up 54.9%.
Eton Pharmaceutcials, Inc.'s EBITDA was $14.2M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 3117.0% from the same quarter a year earlier. Against the prior quarter it is up 300.0%.
Eton Pharmaceutcials, Inc. reported $11.6M in net income in Q2 2026. This represents an increase of 547.9% from the same quarter a year earlier. Against the prior quarter it is up 645.0%.
Eton Pharmaceutcials, Inc. earned $0.35 per diluted share (EPS) in Q2 2026. This represents an increase of 450.0% from the same quarter a year earlier. Against the prior quarter it is up 600.0%.
Cash & Balance Sheet
Eton Pharmaceutcials, Inc. generated $7.3M in free cash flow in Q2 2026, representing cash available after capex. This represents a decrease of 8.9% from the same quarter a year earlier. Against the prior quarter it is down 1.1%.
Eton Pharmaceutcials, Inc. held $26.8M in cash against $19.1M in long-term debt as of Q2 2026.
Not reported for Q2 2026.
Margins & Returns
Eton Pharmaceutcials, Inc.'s gross margin was 67.6% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is up 4.6 percentage points from the same quarter a year earlier. Against the prior quarter it is up 6.9 percentage points.
Eton Pharmaceutcials, Inc.'s operating margin was 34.0% in Q2 2026, reflecting core business profitability. This is up 41.8 percentage points from the same quarter a year earlier. Against the prior quarter it is up 24.1 percentage points.
Eton Pharmaceutcials, Inc.'s net profit margin was 30.8% in Q2 2026, showing the share of revenue converted to profit. This is up 44.5 percentage points from the same quarter a year earlier. Against the prior quarter it is up 24.4 percentage points.
Eton Pharmaceutcials, Inc.'s ROE was 24.9% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 35.6 percentage points from the same quarter a year earlier. Against the prior quarter it is up 19.8 percentage points.
Capital Allocation
Eton Pharmaceutcials, Inc. invested $993K in research and development in Q2 2026. This represents a decrease of 73.2% from the same quarter a year earlier. Against the prior quarter it is down 47.0%.
Eton Pharmaceutcials, Inc. invested $5K in capex in Q2 2026, funding long-term assets and infrastructure. Against the prior quarter it is down 93.3%.
Not reported for Q2 2026.
ETON Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $37.6M+98.6% | $24.3M+40.4% | $21.3M+82.7% | $22.5M+117.5% | $18.9M+108.6% | $17.3M+116.9% | $11.6M+59.3% | $10.3M+46.9% |
| Cost of Revenue | $12.2M+73.8% | $9.5M+28.4% | $8.2M+58.2% | $14.6M+263.1% | $7.0M+103.1% | $7.4M+150.8% | $5.2M+40.4% | $4.0M+53.2% |
| Gross Profit | $25.4M+113.1% | $14.7M+49.4% | $13.1M+102.3% | $7.9M+24.6% | $11.9M+111.9% | $9.9M+96.9% | $6.5M+78.4% | $6.3M+43.1% |
| R&D Expenses | $993K-73.2% | $1.9M+61.5% | $1.8M+104.4% | $1.1M+120.2% | $3.7M+25.0% | $1.2M+78.3% | -$871K-16.8% | $505K-17.9% |
| SG&A Expenses | $11.6M+20.0% | $10.4M+13.9% | $8.9M+31.8% | $8.1M+53.3% | $9.7M+73.3% | $9.2M+77.9% | $6.7M+46.8% | $5.3M+22.0% |
| Operating Income | $12.8M+967.4% | $2.4M+613.6% | $2.5M+291.7% | -$1.4M-367.8% | -$1.5M+49.7% | -$470K+41.3% | $629K+131.6% | $509K+192.9% |
| EBITDA | $14.2M+3117.0% | $3.5M+552.9% | $3.5M+254.1% | -$354K-144.9% | -$470K+82.3% | $543K+195.9% | $983K+158.3% | $788K+320.7% |
| Interest Expense | $1.1M+3.1% | $1.1M-2.3% | $1.4M-9.4% | $1.2M+474.4% | $1.0M+1907.7% | $1.2M+388.7% | $1.5M+272.3% | $211K-21.0% |
| Income Tax | $140K+112.1% | $20K-73.0% | -$69K-179.3% | -$28K+77.8% | $66K+22.2% | $74K | $87K-64.8% | -$126K |
| Net Income | $11.6M+547.9% | $1.6M+198.9% | $1.5M+348.0% | -$1.9M-407.3% | -$2.6M+15.0% | -$1.6M-93.8% | -$598K+73.5% | $627K+208.3% |
| EPS (Basic) | $0.42+520.0% | $0.06+200.0% | $0.06+300.0% | -$0.07-450.0% | -$0.10+16.7% | -$0.06-100.0% | -$0.03+66.7% | $0.02+200.0% |
| EPS (Diluted) | $0.35+450.0% | $0.05+183.3% | N/A | -$0.07-450.0% | -$0.10+16.7% | -$0.06-100.0% | N/A | $0.02+200.0% |
| Diluted Shares (Avg) | 33M+21.9% | 32M+17.3% | N/A | 27M+1.3% | 27M+104225.4% | 27M+104259.0% | N/A | 27M+103131.1% |
ETON Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $115.8M+13.9% | $97.7M+16.3% | $92.1M+21.0% | $104.5M+191.6% | $101.7M+219.5% | $84.0M+172.9% | $76.1M+139.8% | $35.8M+13.7% |
| Current Assets | $68.6M+0.2% | $53.2M+6.6% | $60.6M+47.7% | $72.0M+142.0% | $68.4M+169.1% | $50.0M+105.9% | $41.0M+52.8% | $29.7M+9.5% |
| Cash & Equivalents | $26.8M+5.8% | $19.7M+12.9% | $25.9M+73.7% | $37.1M+83.2% | $25.4M+43.4% | $17.4M+4.6% | $14.9M-30.2% | $20.3M-8.2% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $10.1M-57.4% | $14.5M+6.2% | $15.4M+1.2% | $16.9M+769.7% | $23.8M+1050.4% | $13.6M+487.6% | $15.2M+1572.0% | $1.9M+84.4% |
| Accounts Receivable | $24.9M+72.2% | $13.4M-18.2% | $11.8M+119.3% | $13.1M+134.0% | $14.5M+196.6% | $16.4M+286.8% | $5.4M+57.2% | $5.6M+60.0% |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $69.2M-10.9% | $67.1M+12.6% | $66.0M+27.6% | $81.4M+309.8% | $77.7M+323.3% | $59.6M+289.4% | $51.7M+217.9% | $19.9M+35.7% |
| Current Liabilities | $45.1M+16.9% | $44.2M+74.3% | $38.5M+93.0% | $44.2M+123.9% | $38.6M+111.9% | $25.4M+65.7% | $19.9M+22.8% | $19.7M+89.9% |
| Non-Current Liabilities | $24.1M-38.4% | $22.9M-33.1% | $27.5M-13.5% | $37.2M+29424.6% | $39.1M+26878.6% | $34.2M | $31.7M+144209.1% | $126K-97.0% |
| Long-Term Debt | $19.1M-30.4% | $18.9M-36.9% | $21.8M-27.0% | $27.6M | $27.4M | $30.0M | $29.8M | N/A |
| Total Equity | $46.6M+94.4% | $30.6M+25.2% | $26.2M+7.1% | $23.1M+44.7% | $24.0M+78.0% | $24.4M+57.8% | $24.4M+57.8% | $16.0M-5.4% |
| Retained Earnings | -$99.4M+11.3% | -$110.9M-1.3% | -$112.5M-4.3% | -$114.0M-6.2% | -$112.0M-3.8% | -$109.5M-4.4% | -$107.9M-3.7% | -$107.3M-5.4% |
Not reported in any period shown, so not listed: Goodwill.
ETON Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $7.3M-8.8% | $7.4M+254.3% | -$11.6M-1409.9% | $12.0M+307.4% | $8.0M+534.2% | $2.1M+184.5% | -$765K-297.7% | $3.0M+238.1% |
| Depreciation & Amortization | $1.4M+37.9% | $1.1M+11.6% | $1.0M+186.5% | $1.0M+261.6% | $1.0M+260.2% | $1.0M+332.9% | $355K+9.2% | $279K+46.1% |
| Stock-Based Compensation | N/A | $1.5M+26.5% | N/A | N/A | N/A | $1.2M+46.2% | N/A | $2.4M-0.2% |
| Capital Expenditures | -$5K | $75K | $49K+308.3% | $284K | $0 | $0-100.0% | $12K | $0 |
| Free Cash Flow | $7.3M-8.9% | $7.3M+250.7% | -$11.6M-1392.9% | $11.7M+297.8% | $8.0M+534.2% | $2.1M+184.0% | -$777K-300.8% | $3.0M+238.1% |
| Investing Cash Flow | $5K | -$15.1M | -$49K+99.9% | -$284K | $0 | $0+100.0% | -$38.1M-4820.3% | $0 |
| Financing Cash Flow | -$76K | $1.4M+252.5% | $421K-98.7% | $0+100.0% | $0+100.0% | $394K+204.2% | $33.6M+11519.0% | -$385K-4.3% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
ETON Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 67.6%+4.6pp | 60.7%+3.7pp | 61.6%+6.0pp | 35.0%-26.1pp | 63.0%+1.0pp | 57.1%-5.8pp | 55.6%+6.0pp | 61.0%-1.6pp |
| Operating Margin | 34.0%+41.8pp | 10.0%+12.7pp | 11.6%+6.2pp | -6.1%-11.0pp | -7.8%+24.6pp | -2.7%+7.3pp | 5.4%+32.6pp | 4.9%+12.7pp |
| Net Margin | 30.8%+44.5pp | 6.4%+15.5pp | 7.0%+12.1pp | -8.6%-14.6pp | -13.7%+19.9pp | -9.1%+1.1pp | -5.1%+25.7pp | 6.1%+14.3pp |
| Return on Equity | 24.9%+35.6pp | 5.1%+11.5pp | 5.7%+8.1pp | -8.3%-12.3pp | -10.8%+11.8pp | -6.4%-1.2pp | -2.4%+12.1pp | 3.9%+7.3pp |
| Return on Assets | 10.0%+12.5pp | 1.6%+3.5pp | 1.6%+2.4pp | -1.8%-3.6pp | -2.5%+7.0pp | -1.9%+0.8pp | -0.8%+6.3pp | 1.8%+3.6pp |
| Current Ratio | 1.52-0.3x | 1.21-0.8x | 1.57-0.5x | 1.63+0.1x | 1.77+0.4x | 1.97+0.4x | 2.06+0.4x | 1.51-1.1x |
| Debt-to-Equity | 0.41-0.7x | 0.62-0.6x | 0.83-0.4x | 1.190.0x | 1.14-0.2x | 1.23+0.2x | 1.22+1.2x | 1.24+1.0x |
| Asset Turnover | 0.32+0.1x | 0.250.0x | 0.23+0.1x | 0.21-0.1x | 0.19-0.1x | 0.21-0.1x | 0.15-0.1x | 0.29+0.1x |
| FCF Margin | 19.3%-22.8pp | 30.2%+18.1pp | -54.5%-47.8pp | 52.3%+23.7pp | 42.0%+28.2pp | 12.1%+43.3pp | -6.7%-12.0pp | 28.6%+16.2pp |
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Eton Pharmaceutcials, Inc. ETON | FY2025 | $80.0M | -$4.6M | -5.8% | $1.6B | 51/100 |
| Kamada Ltd KMDA | FY2025 | $180.5M | $20.2M | 11.2% | $468.0M | 41/100 |
| Evolus, Inc. EOLS | FY2025 | $297.2M | -$51.6M | -17.4% | $487.5M | 34/100 |
| Emergent Biosolutions, Inc. EBS | FY2025 | $742.9M | $52.6M | 7.1% | $356.3M | 36/100 |
| Aquestive Therapeutics, Inc. AQST | FY2025 | $44.5M | -$83.8M | N/A | $578.6M | 35/100 |
| Esperion Therapeutics, Inc. ESPR | FY2025 | $403.1M | -$22.7M | -5.6% | $819.5M | 30/100 |
Where Eton Pharmaceutcials, Inc. Ranks
Frequently Asked Questions
What is Eton Pharmaceutcials, Inc.'s annual revenue?
Eton Pharmaceutcials, Inc. (ETON) reported $80.0M in total revenue for fiscal year 2025. This represents a 104.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Eton Pharmaceutcials, Inc.'s revenue growing?
Eton Pharmaceutcials, Inc. (ETON) revenue grew by 104.9% year-over-year, from $39.0M to $80.0M in fiscal year 2025.
Is Eton Pharmaceutcials, Inc. profitable?
No, Eton Pharmaceutcials, Inc. (ETON) reported a net income of -$4.6M in fiscal year 2025, with a net profit margin of -5.8%.
What is Eton Pharmaceutcials, Inc.'s EBITDA?
Eton Pharmaceutcials, Inc. (ETON) had EBITDA of $3.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Eton Pharmaceutcials, Inc. have?
As of fiscal year 2025, Eton Pharmaceutcials, Inc. (ETON) had $25.9M in cash and equivalents against $21.8M in long-term debt.
What is Eton Pharmaceutcials, Inc.'s gross margin?
Eton Pharmaceutcials, Inc. (ETON) had a gross margin of 53.5% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Eton Pharmaceutcials, Inc.'s operating margin?
Eton Pharmaceutcials, Inc. (ETON) had an operating margin of -1.1% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Eton Pharmaceutcials, Inc.'s net profit margin?
Eton Pharmaceutcials, Inc. (ETON) had a net profit margin of -5.8% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Eton Pharmaceutcials, Inc.'s return on equity (ROE)?
Eton Pharmaceutcials, Inc. (ETON) has a return on equity of -17.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Eton Pharmaceutcials, Inc.'s free cash flow?
Eton Pharmaceutcials, Inc. (ETON) generated $10.2M in free cash flow during fiscal year 2025. This represents a 980.7% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Eton Pharmaceutcials, Inc.'s operating cash flow?
Eton Pharmaceutcials, Inc. (ETON) generated $10.5M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Eton Pharmaceutcials, Inc.'s total assets?
Eton Pharmaceutcials, Inc. (ETON) had $92.1M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Eton Pharmaceutcials, Inc.'s capital expenditures?
Eton Pharmaceutcials, Inc. (ETON) invested $333K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Eton Pharmaceutcials, Inc. spend on research and development?
Eton Pharmaceutcials, Inc. (ETON) invested $7.8M in research and development during fiscal year 2025.
What is Eton Pharmaceutcials, Inc.'s current ratio?
Eton Pharmaceutcials, Inc. (ETON) had a current ratio of 1.57 as of fiscal year 2025, which is generally considered healthy.
What is Eton Pharmaceutcials, Inc.'s debt-to-equity ratio?
Eton Pharmaceutcials, Inc. (ETON) had a debt-to-equity ratio of 0.83 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Eton Pharmaceutcials, Inc.'s return on assets (ROA)?
Eton Pharmaceutcials, Inc. (ETON) had a return on assets of -5.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Eton Pharmaceutcials, Inc.'s P/E ratio?
Eton Pharmaceutcials, Inc. (ETON) trades at 124x earnings, its market capitalization divided by net income of $12.7M net income, trailing 12 months to June 30, 2026. The market capitalization is $1.6B as of Oct 8, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Eton Pharmaceutcials, Inc.'s price-to-sales ratio?
Eton Pharmaceutcials, Inc. (ETON) trades at 14.9x sales, its market capitalization divided by revenue of $105.6M revenue, trailing 12 months to June 30, 2026. The market capitalization is $1.6B as of Oct 8, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Eton Pharmaceutcials, Inc.'s Altman Z-Score?
Eton Pharmaceutcials, Inc. (ETON) has an Altman Z-Score of 13.68, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Eton Pharmaceutcials, Inc.'s Piotroski F-Score?
Eton Pharmaceutcials, Inc. (ETON) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Eton Pharmaceutcials, Inc.'s earnings high quality?
Eton Pharmaceutcials, Inc. (ETON) reported a net loss of $4.6M while generating $10.5M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Eton Pharmaceutcials, Inc. cover its interest payments?
Eton Pharmaceutcials, Inc. (ETON) reported an operating loss of $844K against $4.8M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Eton Pharmaceutcials, Inc.?
Eton Pharmaceutcials, Inc. (ETON) scores 51 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.